Weight-Loss Drugs Show Signs of Slowing Biological Aging

Popular weight-loss drugs, specifically GLP-1 agonists, are now showing potential to slow down the biological aging process in patients, according to statements from major drugmakers Eli Lilly and Novo Nordisk. These findings were presented over the weekend at the Aging Research & Drug Discovery conference. The companies analyzed data from patients using their GLP-1 drugs, which are primarily prescribed for weight loss and diabetes management, by employing molecular "aging clocks." These clocks measure biological age by examining changes in DNA or tracking key protein levels that accumulate over time. Both Eli Lilly and Novo Nordisk observed that overweight or diabetic patients administered these drugs exhibited a reduced biological age when contrasted with control groups receiving a placebo. The magnitude of this reduction varied, influenced by the specific type of aging clock utilized and the biological tissue being examined. Overall, the observed difference in biological age was approximately "two to three years," as stated by Nikolaj Roed, a global project leader at Novo Nordisk. Roed indicated that the company has consistently observed "improved biological age in our patients across trials and across different tissues." These emerging results are fueling speculation among scientists that GLP-1 drugs may be targeting fundamental mechanisms of aging, potentially positioning them as genuine longevity treatments. Steve Horvath, a professor at the University of California, Los Angeles, and a pioneer in the development of aging clocks, commented that "Two years is a pretty strong effect, in my book." Horvath suggested that the accumulating data could provide "evidence that these GLP-1 drugs are actually what is known as geroprotectors, medications that slow or possibly even reverse biologic aging." While the quest for scientific remedies for old age has not yet yielded definitive breakthroughs, some researchers believe Novo Nordisk's drug semaglutide, marketed as Ozempic and Wegovy, is approaching such a goal. Vadim Gladyshev, a Harvard biologist who collaborated with Novo Nordisk on molecular measurements, stated, "In an unhealthy population, I do think it’s an anti-aging drug. But in a healthy population, no one knows." The primary mechanism by which these drugs induce weight loss involves their action on the GLP-1 receptor, which influences appetite and glucose regulation. However, the observed effects on biological aging suggest a broader impact on cellular processes associated with aging.